Year: 2021

Key financial highlightsRevenue growth of 9.7 % reaching $38.4 M for Q1-FY2022 from $35.0 M for Q1-FY2021; Adjusted EBITDA1 reached $4.0 M, or 10.5 % of revenues, for Q1-FY2022, compared to $3.5 M, or 9.9 % of revenues, for Q1-FY2021; Net earnings amounted to $0.6 M or $0.007 per share for Q1-FY2022 compared to net earnings of $1.0 M or $0.013 per share for Q1-FY2021; Consolidated backlog of $122.8 M at the end of the quarter; and Strong financial position with a net debt1 of $3.4 M.All amounts in Canadian dollars unless otherwise stated. QUEBEC CITY, Nov. 10, 2021 (GLOBE NEWSWIRE) — (TSXV: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) announces its financial results for the first quarter of fiscal year 2022 ended September 30, 2021. “We are starting our new fiscal year on a strong financial basis supported...

Net Revenue up 54% to $215.5 Million With Net Income Attributable to the Company of $7.9 Million and a 191% Increase in Adjusted EBITDA to $17.4 Million CITY OF INDUSTRY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG), a leading food distributor to Asian restaurants across the Southeast, Pacific and Mountain West regions of the United States (the “Company” or “HF Foods”), reported record financial results for the third quarter ended September 30, 2021.   Third Quarter 2021 Financial SummaryNet revenue increased 54.0% to $215.5 million compared to $139.9 million in the third quarter of 2020. Gross profit increased 66.6% to $41.9 million, or 19.4% of net revenue, from $25.2 million, or 18.0% of net revenue, in the third quarter of 2020. Net income attributable to the Company increased significantly...

CHICAGO, Nov. 10, 2021 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a leading global alternative asset management solutions provider, today reported strong results for the third fiscal quarter ended September 30, 2021 and announced that the Board of Directors approved an 11% increase in the firm’s quarterly dividend. “The third quarter was a strong one with good investment results, fundraising and business performance,” said Michael Sacks, Chairman and Chief Executive Officer of GCM Grosvenor. “Our outlook with regard to the remainder of 2021 and 2022 is positive and as a result our Board of Directors has increased our dividend 11% from $0.09 per share to $0.10 per share.” Assets Under ManagementAssets Under Management increased 20% from September 30, 2020 (the “prior year”) and increased 5% from June 30, 2021 (the...

Total Revenue Increased 34% to $1.67 million; OVA1 Volume Grew 19% to 4,281 Units Successful Completion of Proof of Concept with Harvard Dana Farber Cancer Institute Collaboration Achieved Over 194 Million Covered Lives for OVA1 Conference Call and Webcast Today at 8:30 a.m. ET AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the third quarter ended September 30, 2021. “We are very pleased with the growth in positive medical policy coverage with the addition of AIM Specialty Health’s Clinical Appropriateness Guidelines and Medicaid coverage and credentialing for OVA1. In addition, in spite of renewed COVID-19 restrictions we were able to grow in specific markets,”...

CALGARY, Alberta, Nov. 10, 2021 (GLOBE NEWSWIRE) — InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) (“InPlay” or the “Company”) is pleased to announce its financial and operating results for the three and nine months ended September 30, 2021. InPlay’s condensed unaudited interim financial statements and notes, as well as Management’s Discussion and Analysis (“MD&A”) for the three and nine months ended September 30, 2021 will be available at “www.sedar.com” and our website at “www.inplayoil.com”.   We are very pleased to present our third quarter financial and operating results in which the efficient execution of our operational and capital program, coupled with the significantly improved commodity price environment, has allowed us to achieve record production and financial results.   Third Quarter 2021 Financial & Operating...

Company to Host Conference Call Today at 9 a.m. EST CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) —  F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced third quarter 2021 financial results and a corporate update. Eliot Forster, CEO of F-star Therapeutics, Inc., said, “A year on from listing on NASDAQ, we have delivered on our planned milestones, and through them value for patients, partners and our investors. Our agile, tenacious approach, working with world-leading investigators, continues to further F-star’s mission to bring our unique bispecific antibodies to patients who need them most. We continue to advance four clinical programs,...

LONDON and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third quarter ended September 30, 2021 and provided an update on recent progress. During the quarter, MeiraGTx continued to progress the Phase 3 Lumeos Trial of botaretigene sparoparvovec, formerly referred to as AAV5-RPGR, in X-linked retinitis pigmentosa (XLRP) with its partner Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, with subjects currently screening. Data from the Phase 1/2 dose escalation study in RPGR patients presented at the EURETINA 2021 Virtual Meeting showed treatment with botaretigene sparoparvovec reverses the course of disease progression when retinal...